» Articles » PMID: 1740178

Leishmania Amazonensis Infection: a Comparison of in Vivo Leishmanicidal Mechanisms Between Immunized and Naive Infected BALB/c Mice

Overview
Journal Exp Parasitol
Specialty Parasitology
Date 1992 Mar 1
PMID 1740178
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro studies have shown that both macrophage activation and destruction of parasitized macrophages lead to leishmania destruction. The relative role played by such mechanisms in vivo have not been properly evaluated. We took advantage of the model of intravenous immunization with solubilized leishmanial antigen which renders partially resistant the otherwise highly susceptible BALB/c mice to address this issue avoiding the interference of different genetic backgrounds. Leishmania destruction occurred in three situations: destruction of the parasitized macrophage, which were in close contact with lymphocytes or eosinophils; extracellular damage, always surrounded by small foci of granulocytes; and parasite damage inside activated macrophages. Destruction of the parasitized macrophages was frequently seen in immunized and protected animals. Our observations suggest that destruction of parasite-loaded macrophages is an important mechanism of host protection in experimental cutaneous leishmaniasis.

Citing Articles

The absence of eosinophils is associated with early metastatic lesions in Leishmania amazonensis-infected mice.

Almeida G, Luehring T, Paixao P, Pedro Soares R, de Barros A, Lima do Monte-Neto R Mem Inst Oswaldo Cruz. 2024; 119:e220242.

PMID: 38198296 PMC: 10777375. DOI: 10.1590/0074-02760220242.


Eosinophils, but Not Type 2 Innate Lymphoid Cells, Are the Predominant Source of Interleukin 4 during the Innate Phase of Infection.

Sasse C, Barinberg D, Obermeyer S, Debus A, Schleicher U, Bogdan C Pathogens. 2022; 11(8).

PMID: 35894051 PMC: 9331382. DOI: 10.3390/pathogens11080828.


Low-dose UVB contributes to host resistance against Leishmania amazonensis infection in mice through induction of gamma interferon and tumor necrosis factor alpha cytokines.

Khaskhely N, Maruno M, Uezato H, Takamiyagi A, Ramzi S, Kariya K Clin Diagn Lab Immunol. 2002; 9(3):677-86.

PMID: 11986277 PMC: 119974. DOI: 10.1128/cdli.9.3.677-686.2002.